Company Profile For Amgen Inc.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company operates in human therapeutics. It markets human therapeutic products in the areas of supportive cancer care, nephrology and inflammation. Its principal products include Aranesp (darbepoetin alfa), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and Enbrel (etanercept). Aranesp and EPOGEN stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis-stimulating agents (ESAs). On January 4, 2008, the Company completed the acquisition of Dompe Biotec, S.p.A.

BRIEF: For the nine months ended 30 September 2009, Amgen, Inc.'s revenues decreased 4% to $10.83B. Net income increased 17% to $3.67B. Revenues reflect a decrease in income from product sales and lower other revenue. Net income was offset by decreased cost of sales, lower research & development expenses, a decrease in selling, general & administrative expenses, lower other charges and lower interest & other income, net.